Skip to content

Serotonin: all studies

Page 123 of 400: studies 1,221 to 1,230 of 3,999, newest first. Back to the serotonin overview

Research

Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 1, 2025 Marta L.c. Palhas, Rémi Corne, Raymond Mongeau 4 citations

After years of restrictions due to concerns about their potentially harmful effects, research on psychedelics has entered a new era. Increasing attention has been directed toward their immense therapeutic potential, particularly for psychiatric disorders. Pre-clinical and clinical studies have consistently demonstrated that psychedelic treatments produce therapeutic effects within hours of...

Inhibition of SERT and NMDAR synergistically confers rapid antidepressant effects of ketamine

National Science Review September 5, 2025 Huoqing Luo, Ming Chen, Yingjie Ning et al. 1 citation

-methyl-d-aspartate receptor (NMDAR) blockade is crucial for the rapid antidepressant effects of ketamine, the involvement of other mechanisms remains contentious, particularly regarding the role of serotonin, a key neurotransmitter in the target of traditional antidepressants. Here, we demonstrate that ketamine elevates serotonin levels by inhibiting the serotonin transporter (SERT). A...

DOI: 10.1093/nsr/nwaf367 (opens in new tab) Full text (opens in new tab) Ketamine Antidepressant Nmda receptor Neurotransmitter +6

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS

The International Journal of Neuropsychopharmacology August 1, 2025 Giovanni Martinotti, Clara Cavallotto, Giacomo D’andrea et al.

Abstract Background Among the innovative treatments investigated for depression, psilocybin appears to play an extremely promising role, with several studies showing remission rates up to 70% in patients with treatment-resistant depression (TRD) treated with protocols involving a single or double dose administration [1,2]. Psilocybin is a psychedelic compound belonging to the tryptamine class,...

The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.

Psychopharmacology August 1, 2025 Leah M Salinsky, Christina R Merritt, Erik J. Garcia et al. 8 citations

Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liability of cocaine is reliant upon inhibition of dopamine (DA) reuptake and consequent increase in DA efflux in meso-corticolimbic circuitry that controls reward and motivation. Cocaine also increases serotonin (5-HT) efflux which is integral in cocaine...

DOI: 10.1007/s00213-025-06765-3 (opens in new tab) Full text (opens in new tab) Serotonin −-2,5-dimethoxy-4-iodoamphetamine 5-ht2ar Behavioral economics +3

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology July 28, 2025 Omar Qureshi, Jamie Cowley, Ashley Pegg et al. 5 citations

Psychedelic drugs that activate 5-HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti-inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune responses, including inhibiting...

DOI: 10.1111/bph.70138 (opens in new tab) Full text (opens in new tab) 5-ht2a receptor 5‐ht2a receptor Immune system Neuroinflammation +4

Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2

International Journal of Molecular Sciences July 26, 2025 Lena M. Rudy, Michał M. Godlewski 2 citations

Sleep paralysis (SP), an REM parasomnia, can be characterized as one of the symptoms of narcolepsy. The SP phenomenon involves regaining meta-consciousness by the dreamer during REM, when the physiological atonia of skeletal muscles is accompanied by visual and auditory hallucinations that are perceived as vivid and distressing nightmares. Sensory impressions include personification of an...

Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function.

Cureus July 1, 2025 Akshita Suleria, Sakshi Verma, Khanij Arya et al.

Lysergic acid diethylamide (LSD) is an ergot-derived psychedelic agent that produces perceptual and psychic effects of heightened sensations by acting on the dopaminergic, adrenergic, and serotonergic pathways in the brain and periphery, with 5-hydroxytryptamine 2A (5-HT2A) as the primary target molecule. Its action on these receptors in the central nervous system is comparatively well studied...

What fMRI studies say about the nature of the psychedelic effect: a scoping review

Frontiers in Neuroscience July 1, 2025 Michal Beneš, Tomáš Páleníček, Jiřı́ Horáček 4 citations

Research on psychedelic drugs, such as psilocybin, LSD or DMT, is a burgeoning field, with an increasing number of studies showing their promise in treatment of mental disorders as well as examining their mechanism of action. Determining their effect on the brain is crucial from clinical standpoint, but also offers highly promising avenues of advancement in basic neuroscience—functional...

DOI: 10.3389/fnins.2025.1606798 (opens in new tab) Psilocybin Serotonergic Cognitive psychology Modality human–computer interaction +1

Molecular, haemodynamic and functional effects of LSD in the human brain

medRxiv June 18, 2025 Drummond E-Wen Mcculloch, Kristian Larsen, Annette Johansen et al. preprint

In this study, we provide the first study to integrate molecular and functional neuroimaging during psychedelic drug effects in humans. Using simultaneous PET-MRI technology, we describe multiple brain actions of lysergic acid diethylamide (LSD) in healthy volunteers. We quantify the occupancy of LSD at cerebral serotonin 2A receptors and show that LSD increases global cerebral blood flow and...

Neurochemical, Neurocircuitry, and Psychopathological Mechanisms of PTSD: Emerging Pharmacotherapies and Clinical Perspectives.

ACS Chemical Neuroscience June 10, 2025 Santosh Kumar Prajapati, Shreyasi Majumdar, Snehapriya Murari et al. 14 citations

Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition triggered by exposure to traumatic events, with complex neurobiological anomalies that remain incompletely understood. This review aims to comprehensively explore the neurocircuitry, neurochemical dysregulation, and emerging pharmacological targets associated with PTSD, offering a consolidated framework for developing...